BioCentury | Jul 25, 2019
Product Development

The universe of universal flu vaccines

...For example, delivery of conserved portions of surface glycoprotein HA alone, without antigens from other influenza proteins...
...all A and B strains, consists of nine peptides from conserved regions of three major influenza proteins...
BioCentury | Feb 22, 2018
Product R&D

Shooting for the universe

...Ltd. Flu-v is a peptide vaccine that targets T cell responses to a trio of influenza proteins...
BioCentury | Jan 7, 2010
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus Not applicable In vitro studies identified a network of H1N1 influenza protein-human host protein interactions that could be targeted to help treat...
BioCentury | Nov 10, 2008
Company News

Protein Sciences, Vaxine deal

Vaxine made an unsolicited bid to acquire fellow vaccine company Protein Sciences in a stock deal that could exceed $60 million. Protein Sciences said it is reviewing the offer. The companies are already collaborating on...
BioCentury | Oct 31, 2005
Clinical News

FluINsure: Phase II started

IDB started a placebo-controlled, Canadian Phase II trial in 160 healthy children 3 to 12 years of age. The vaccine also is in Phase II trials in adults. ID Biomedical Corp. (TSX:IDB; IDBE), Vancouver, B.C....
BioCentury | Oct 25, 2005
Clinical News

IDB gives vaccine updates

ID Biomedical (TSX:IDB; IDBE) said that, based on a pre-IND meeting with FDA, it does not expect to begin pediatric trials of StreptAvax vaccine prior to 2007. In January, IDB said it expected to begin...
BioCentury | Oct 17, 2005
Strategy

Flu vaccine manufacturers

...that includes hemagglutinin; vaccine can be made from both egg-derived antigens as well as recombinant influenza proteins...
BioCentury | Jan 17, 2005
Clinical News

FluINsure infectious data

In a placebo-controlled, Canadian trial in 1,349 healthy subjects there was a significant rise in serum hemagglutination-inhibiting (HAI) antibody titers for all 3 vaccine viruses compared to placebo (p<=0.001). Also, salivary secretory IgA specific for...
BioCentury | Oct 11, 2004
Politics, Policy & Law

Flu vaccine pipeline

Flu vaccine pipeline Company Product Status Chiron Cell-culture based vaccine Ph II Intranasal vaccine Preclin Crucell/ Sanofi-Aventis Vaccine based on Crucell's PER.C6 cell technology Preclin GlaxoSmithKline Influenza subunit vaccine Ph I ID Biomedical FluINsure intranasal...
BioCentury | Jul 26, 2004
Clinical News

FluInsure infectious data

In a Canadian field trial in 1,349 healthy volunteers, FluInsure protected against culture confirmed influenza illness compared to placebo (7/904 vs. 9/443, p=0.045). Volunteers received 1 or 2 doses of FluInsure or placebo. IDB said...
Items per page:
1 - 10 of 26